FORM 51-102F3

MATERIAL CHANGE REPORT

Item 1 Name and Address of Company

Canadian International Pharma Corp.
2489 Bellevue Avenue
West Vancouver, British Columbia V7V 1E1

(the “Company” or “CIPC”)

Item 2 Date of Material Change

January 5, 2016

Item 3 News Release

Issued in West Vancouver, B.C. on January 5, 2016 and disseminated through the facilities of Market News and Stockwatch.

Item 4 Summary of Material Change

CIPC announced extension of Non-Brokered Private Placement.

Item 5 Full Description of Material Change

5.1 Full Description of Material Change

CIPC announced that it has extended the closing of its non-brokered private placement offering announced on November 20, 2015. As well, in accordance with the rules of the NEX Board of the TSX Venture Exchange, the amount of the proposed financing has been reduced. As a result, and subject to regulatory approval, the Company intends to proceed with a non-brokered private placement to raise up to $500,000 by the issuance of up to 7,142,857 non-flow through units (the “Units”) at $0.07 per Unit. Each Unit will consist of one common share and one share purchase warrant, with each warrant entitling the holder to purchase an additional common share for a period of one year at an exercise price of $0.15. With respect to this private placement, the Company may pay finders’ fees in the amount of 10% (payable in cash or Units), based on the sale of the Units purchased by subscribers introduced to the Company by such finders.

The Company intends to use the proceeds from this private placement for financing the continued development and pursuit of business opportunities in the area of pharmaceutical and neutraceutical manufacturing and distribution and for general working capital purposes.

About Canadian International Pharma Corp.

Canadian International Pharma Corp (“CIPC” or the “Company”) intends to develop a multi-faceted generic drug manufacturing, distribution and testing / certification company. Once CIPC has obtained its expected Canadian Good Manufacturing (“GMP”) license, it intends to focus on applying GMP standards to generics manufactured outside of Canada so that these generics can be certified and tested on an ongoing basis as meeting Canadian standards. The Company also plans to utilize its anticipated GMP license and its planned Canadian manufacturing facility to produce generics and neutraceuticals in Canada for the Canadian market. CIPC also plans to take advantage of international market demands for Canadian and US manufactured neutraceuticals and, in connection therewith, CIPC intends to negotiate and establish distribution agreements with Canadian and US neutraceuticals manufacturers.
For further information, contact Mr. Clive Shallow, Shareholder Communications, at 604-922-2030, or visit the Company’s website at www.canpharmacorp.ca.

5.2 Disclosure for Restructuring Transactions

Not Applicable.

Item 6 Reliance on subsection 7.1(2) of National Instrument 51-102

Not applicable

Item 7 Omitted Information

No information has been intentionally omitted from this form.

Item 8 Executive Officers

Douglas L. Mason, CEO
Sead Hamzagic, CFO

Further information may be obtained from Bruce E. Morley, director of the Company, 2489 Bellevue Avenue, West Vancouver, British Columbia, V7V 1E1, (604) 922-2030

Item 9 Date of Report

This report is dated the 5th day of January, 2016.